文献速递眼底病与葡萄膜炎

萎缩型年龄相关性黄斑变性与晚发型Stargardt病的疾病进展差异

Differential Disease Progression in Atrophic Age-Related Macular Degeneration and Late-Onset Stargardt Disease.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

本研究纵向比较了继发于年龄相关性黄斑变性(AMD)和晚发型Stargardt病(STGD1)的视网膜色素上皮(RPE)萎缩的疾病进程。AMD组151例(226眼),晚发型STGD1组38例(66眼),中位随访2.3年。AMD的萎缩进展速度显著快于晚发型STGD1(0.28 mm/年 vs 0.23 mm/年,P=0.030),晚发型STGD1的中心凹存活时间显著长于AMD(8.60年 vs 3.35年,P=0.005)。

要点

  • AMD组RPE萎缩进展速度显著快于晚发型STGD1组(0.28 mm/年 vs 0.23 mm/年,P=0.030)。
  • 晚发型STGD1组中心凹中位存活时间显著长于AMD组(8.60年 vs 3.35年,P=0.005)。
  • 两组BCVA下降≥3行的趋势为晚发型STGD1组更晚(5.97年 vs 4.37年),但差异无统计学意义(P=0.382)。

核心结论

  • 这些自然病史数据表明AMD与晚发型STGD1的疾病进展存在差异。
  • 结果强调了对表现为RPE萎缩的老年患者进行精细表型分型对于预后和干预试验设计的重要性。

研究设计与样本

  • 纵向研究,纳入继发于AMD的RPE萎缩患者151例(226眼)和继发于晚发型STGD1的RPE萎缩患者38例(66眼)。
  • 采用眼底自发荧光、近红外反射成像和最佳矫正视力(BCVA)进行纵向检查。
  • 使用半自动软件量化RPE萎缩面积,基于自发荧光和近红外反射图像评估中心凹状态。
  • 采用混合效应模型比较萎缩进展率,使用Turnbull估计器分析BCVA下降和中心凹完整性丧失。

主要发现

  • AMD组平均基线年龄74.2岁(SD 7.6),晚发型STGD1组63.4岁(SD 9.9),P=1.1×10⁻⁷。
  • 中位随访时间2.3年(四分位距2.7)。
  • 平方根萎缩进展速度AMD组显著快于晚发型STGD1组(0.28 mm/年[SE 0.01] vs 0.23 mm/年[SE 0.03],P=0.030)。
  • 晚发型STGD1组中心凹中位存活时间显著长于AMD组(8.60年 vs 3.35年,P=0.005)。
  • BCVA下降≥3行的中位时间晚发型STGD1组为5.97年,AMD组为4.37年,差异无统计学意义(P=0.382)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the disease course of retinal pigment epithelium (RPE) atrophy secondary to age-related macula degeneratio (AMD) and late-onset Stargardt disease (STGD1). METHODS: Patients were examined longitudinally by fundus autofluorescence, near-infrared reflectance imaging, and best-corrected visual acuity (BCVA). Areas of RPE atrophy were quantified using semi-automated software, and the status of the fovea was evaluated based on autofluorescence and near-infrared reflectance images. Mixed-effects models were used to compare atrophy progression rates. BCVA loss and loss of foveal integrity were analyzed using Turnbull's estimator. RESULTS: A total of 151 patients (226 eyes) with RPE atrophy secondary to AMD and 38 patients (66 eyes) with RPE atrophy secondary to late-onset STGD1 were examined for a median time of 2.3 years (interquartile range, 2.7). Mean baseline age was 74.2 years (SD, 7.6) in AMD and 63.4 (SD, 9.9) in late-onset STGD1 (P = 1.1 × 10-7). Square root atrophy progression was significantly faster in AMD when compared with late-onset STGD1 (0.28 mm/year [SE, 0.01] vs. 0.23 [SE, 0.03]; P = 0.030). In late-onset STGD1, the median survival of the fovea was significantly longer when compared with eyes with AMD (8.60 vs. 3.35 years; P = 0.005) with a trend to a later BCVA loss of ≥3 lines (5.97 vs. 4.37 years; P = 0.382). CONCLUSIONS: These natural history data indicate differential disease progression in AMD versus late-onset STGD1. The results underline the relevance of refined phenotyping in elderly patients presenting with RPE atrophy in regard to prognosis and design of interventional trials.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Lindner M, Lambertus S, Mauschitz MM, et al. Differential Disease Progression in Atrophic Age-Related Macular Degeneration and Late-Onset Stargardt Disease. Invest Ophthalmol Vis Sci. 2017. PMID: 28288486. doi:10.1167/iovs.16-20980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。